Search
SOLACI Congress
HomeStructural heart diseaseValvular Aortic Valve

Valvular Aortic Valve

View Category
Antithrombotic Anticoagulants

TAVR and Anticoagulation: Direct Anticoagulant Agents or Vitamin K Inhibitors?

In some patients, using an anticoagulant agent is not an option, it is just prescribed. Based on...
solaci -
Learn More
Antiplatelet

Thrombotic and Bleeding Risk after TAVR: Quick Tips to Stay Up to Date

Transcatheter aortic valve replacement (TAVR) is an increasingly frequent option for patients with severe aortic stenosis across...
solaci -
Learn More
Structural heart disease

SAPIEN 3 Ultra: Lower Incidence of Paravalvular Regurgitation?

Paravalvular regurgitation after transcatheter aortic valve replacement (TAVR) have historically been associated with worse clinical outcomes. Even...
solaci -
Learn More
Antiplatelet

ESC 2021 | ENVISAGE-TAVI AF: Surprise with Endoxaban in TAVR and Atrial Fibrillation

The enthusiasm for direct oral anticoagulants after transcatheter aortic valve replacements (TAVR) is waning. At least, when...
solaci -
Learn More
Structural Heart Disease

ESC 2021 | Updated European Society of Cardiology Guidelines for the Management of Valvular Heart Disease

Early intervention in asymptomatic valvular heart disease, age recommendations to decide between TAVR and surgery for aortic...
solaci -
Learn More
Structural heart disease

New Markers of Aortic Stenosis Define Asymptomatic Patients

Asymptomatic aortic stenosis has been keeping us in tense stillness. However, there are new markers capable of...
solaci -
Learn More
Institutional News

SOLACI Webinar | Minimalist TAVI III Summit: A Meeting with the Experts

solaci -
Learn More
Valvular Aortic Valve

TAVR Durability Becomes Irrelevant after TRANSIT Outcomes

The international registry TRANSIT has shown treating degenerated transcatheter aortic valves (TAVs) with a second TAVR is...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Dr. Juan Manuel Pérez - 0
Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...

Cardiac Remodeling After Percutaneous ASD Closure: Should It Be Immediate or Progressive?

Dr. Juan Manuel Pérez - 0
Atrial septal defect (ASD) is a common congenital heart disease that generates a left-to-right shunt, leading to right-side chamber overload and a risk of...

A New Asymptomatic Carotid Stenosis Paradigm? CREST-2 Trial Unified Results

Dr. Juan Manuel Pérez - 0
Severe asymptomatic carotid stenosis continues to be controversial seeing the optimization of intensive medical therapy (IMT) and the availability lower periprocedural risk revascularization techniques....

Institutional News

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

solaci - 0
Our webinar “SELUTION: Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives”, held on November 19, 2025 via Zoom with...

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

solaci - 0
The Latin American Society of Interventional Cardiology invites you to participate in a new virtual scientific event titled “Pulmonary Embolism (PE) in 2025: Risk...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy